EP Patent

EP2167065A1 — Combination therapy for depression

Assigned to General Hospital Corp · Expires 2010-03-31 · 16y expired

What this patent protects

A combination therapy for treating depressive disorders is provided herein. The combination therapy comprises administering an effective amount of bupropion or its metabolites together with at least one serotonin 5-HTIA partial agonist or its metabolites to a patient in need of t…

USPTO Abstract

A combination therapy for treating depressive disorders is provided herein. The combination therapy comprises administering an effective amount of bupropion or its metabolites together with at least one serotonin 5-HTIA partial agonist or its metabolites to a patient in need of treatment of the depressive disorder. Pharmaceutical formulations, including packaged pharmaceutical formulations, comprising this combination are also provided herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP2167065A1
Jurisdiction
EP
Classification
—
Expires
2010-03-31
Drug substance claim
No
Drug product claim
No
Assignee
General Hospital Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.